Syncardia

The US Food and Drug Administration (FDA) has granted approval for SynCardia Systems to conduct a clinical trial, which is designed to evaluate the effectiveness of the SynCardia temporary Total Artificial Heart for permanent use.

In December 2014, the FDA approved the SynCardia investigational device exemption (IDE) application to carry out the destination therapy trial in 19 patients, who do not qualify for a donor heart transplant.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The FDA-approved Freedom portable driver that powers the artificial heart and allows patients increased mobility will be given to clinically stable patients implanted with the SynCardia Total Artificial Heart.

“SynCardia Systems said the SynCardia Total Artificial Heart replaces the native heart’s two failed ventricles and four valves, similar to a donor heart transplant.”

The artificial heart will be implanted in patients who are dying of end-stage biventricular heart failure, which is when the two ventricles of the native heart cannot pump enough blood for the patient to survive.

SynCardia Systems president Michael Garippa said: “This is an important step for SynCardia to advance the use of the Total Artificial Heart to a new group of patients who are not currently eligible for a donor heart.

“The study will generate data on the effective use of the SynCardia Heart in these patients as a way for them to recover from heart failure and continue with a near-normal lifestyle.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The company said the SynCardia Total Artificial Heart replaces the native heart’s two failed ventricles and four valves, similar to a donor heart transplant. The 70cc Total Artificial Heart received FDA approval for use as a bridge to transplant.

Image: French resident Frédéric Thiollet has been supported by the SynCardia Total Artificial Heart for 1,250 days, nearly three and half years. Photo: courtesy of SynCardia Systems, Inc.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact